mTOR as a therapeutic target in patients with gastric cancer
Authors:
- Salah-Eddin Al-BatranSASalah-Eddin Al-Batran
- Michel DucreuxMDMichel Ducreux
- Atsushi OhtsuAOAtsushi Ohtsu
- 5 October 2011
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 130 (3) , 491-496
Abstract
The poor long‐term outcomes associated with current chemotherapy treatment of patients with advanced gastric cancer suggest a need for novel targeted agents that may confer a better survival benefit. Evidence of mammalian target of rapamycin (mTOR) activation has been demonstrated in patient‐derived gastric cancer cells and tumors. This review explores the relevance of the mTOR pathway to gastric cancer pathogenesis and its potential as a therapeutic target in patients with gastric cancer as well as presenting the first available clinical data on mTOR inhibitors in this disease setting. Preclinical data suggest that suppression of the mTOR pathway inhibited the proliferation of gastric cancer cells and delayed tumor progression in in vitro and animal models. In the clinical setting, the mTOR inhibitor everolimus has been active and well tolerated in phase I/II studies of patients with chemotherapy‐refractory metastatic gastric cancer. Based on these promising results, everolimus currently is being investigated as a monotherapy or in combination with chemotherapeutic agents in ongoing phase II/III clinical studies.Keywords
This publication has 55 references indexed in Scilit:
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyJournal of Clinical Investigation, 2011
- mTOR: from growth signal integration to cancer, diabetes and ageingNature Reviews Molecular Cell Biology, 2010
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusJournal of Clinical Investigation, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid TumorsJapanese Journal of Clinical Oncology, 2009
- mTOR mediated anti-cancer drug discoveryDrug Discovery Today: Therapeutic Strategies, 2009
- Relation between outcomes and localisation of p-mTOR expression in gastric cancerBritish Journal of Cancer, 2009
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004